Companies stop the development of antibiotics
Academic research is looking for solutions
Companies stop the development of antibiotics - Academic research is looking for solutions
While multi-resistant microorganisms are increasingly spreading, more and more pharmaceutical companies are withdrawing from antibiotics research. The most recent example is Novartis. Alternative development and financing models are in demand for the less lucrative business with anti-infective active compounds. The research consortium InfectControl 2020, funded by the German Federal Ministry of Education and Research, is an example of the academic and political commitment in Germany to counteract this dangerous trend.